Replies to post #143737 on Biotech Values

[DewDiligence]

[Bruce Booth] must have been reading our back and forth on here. He has the same message and is making almost exactly the same points.

That’s possible, but regardless of where he got the idea for the article, he makes the case succinctly and convincingly, IMO.

Bottom line: Many investors are going to lose a lot of money investing in cancer-drug candidates that lack the differentiation to become big-selling drugs. Of course, each investor thinks this will happen only to other investors and that one can avoid such a fate by being cleverer and more nimble than the others. #msg-76261462 is an example of the (misguided, IMO) mindset that underlies such thinking.